There was no difference in the prevalence of thrombogenic disorders among the survivors of MI according to the presence of normal or diseased coronary arteries.
Background: Short-term treatment with low molecular mass heparin is known to reduce coagulation activity. We have investigated the influence on markers of coagulation activity by long-term treatment with dalteparin, a low molecular mass heparin, in patients with unstable coronary artery disease (CAD).
Methods:
Coagulation activity was monitored in 562 out of the 2267 patients with unstable CAD in the Scandinavian multicenter study FRISC II. All patients were treated with subcutaneous dalteparin 120 IU/kg twice daily for 5-7 days and then randomised to placebo (n=287) or long-term treatment with daltaparin (n=275) for 3 months. Women weighing < 80 kg, and men weighing < 70 kg, received daltaparin 5,000 IU twice daily and above these weight limits the daltaparin dose was 7,500 IU twice daily during longterm treatment. Prothrombin fragment 1+2 (F1+2) and D-dimer were analysed during inhospital daltepadn treatment, during long-term daltaparin/placabo treatment at 6 weeks and 3 months, and at 6 months follow-up. Data are medians with Mann Whitney test.
Results: See Background: Although hyperhomocysteinema is associated with hypercoagulability and piatelet aggregation, and interferes with fibrinolysis, data are scarce regarding the effect of hyperhomocystaine levels on clinical outcome in patients with acute myocardial infarction (AMI). Methods: Homocystaine was determined on admission in 160 consecutive patients with AMI by HPLC methodology with fluorescent detection. Results: Mean homocysteine levels in the entire group were 14±11 micromole/L. Homocysteine levels were higher in male (p<0.01) and non-diabetic patients (p<0.Ol), but were not associated with other risk factors or age (r=0.07, p=0.42). Patients (n=22) with homocysteine 320 micromole/L (34±9) compared with those of lower levels (n=135, 10±4), had a lower incidence of diabetes mellitus (9% vs 28%, p=0.06). There was no significance difference regarding the in-hospital course and indices of infarct size, including peak CPK (p=0.7) and LVEF (p=0.45) in both groups of patients. Among the 112 catheterized patients, those with homocysteine 320 and <20 micromol/L had a similar distribution of the infarct-related artery, number of diseased coronary artedes (p=0.87) and prevalence of multi-vessel coronary artery disease (p=0.9). However, during mean follow-up of 30 months, the patients with higher homocysteine levels had a higher incidence of re-hospitalization for recurrent coronary events (38% vs 17%, p<0.O4) and a higher mortality rate (18% vs 5%, p<0.05). Conclusion: Elevated levels of homocystaine in AMI patients are associated with a higher incidence of recurrent coronary events and mortality. Background and Aim: Advances in interventional cardiology have resulted in a decreased need for emergency coronary artery bypass grafting (EMCABG) following percutaneous coronary interventions (PCI). We sought to determine the current prevalence and predictors of EMCABG.
A retrospective review of all PCIs performed for a 4-year period between 1/2/ 1997 and 12/29/2000 at our institution. Multivadable logistic regression modeling was performed to determine predictors of EMCABG.
